Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Pfizer gets patent for...

    Pfizer gets patent for pneumonia vaccine in India

    Written by Ruby Khatun Khatun Published On 2017-08-23T10:00:47+05:30  |  Updated On 18 Aug 2021 12:18 PM IST

    New Delhi: Multinational drug major Pfizer Inc said it has been granted patent in India for its vaccine Prevenar 13, used for protection against pneumonia.


    The development has, however, been decried by Medicines Sans Frontiers (MSF), an international medical humanitarian organization saying granting the patent on the vaccine could impact its availability.


    The grant of the patent means that Indian pharmaceutical firms will not be able to make the vaccine.


    "We are pleased to note that the validity of the Prevenar 13 patent has now been recognized by the Indian Patent Office," a Pfizer spokesperson said in a statement.


    This vaccine was launched in India in 2010. In its multi-dose vial presentation, this vaccine has been included in the expansion of Indias public immunization program in select states under the GAVI funded platform, it added.


    Criticising the grant of the patent to Pfizer, MSF Asia Regional Coordinator Prince Mathew said: "It is unfair and unacceptable that almost a million children die each year from pneumonia, even though a life-saving vaccine is available."


    Stating that the development would hit access to the vaccine, he said children everywhere have a right to be protected from pneumonia, but many governments cannot afford the prices set by Pfizer.


    Pfizer, however, said it remained committed towards further enhancing access of this vaccine in India, both in the market as well as through the partnership with the government to expand introduction in the public program.


    "Prevenar 13 provides the broadest serotype coverage of any pneumococcal conjugate vaccine available in the world today," the company spokesperson said.


    MSF said it had challenged Pfizer's "unmerited patent claims" in India after the same patent was revoked by the European Patent Office (EPO) in 2016.


    "The patent is also being legally challenged in South Korea and before the US Patent Trademark Appeal Board," MSF said.

    EPOEuropean Patent OfficeIndiaIndian pharmaceutical firmsMedicines Sans FrontiersMSFpartnershippatentPfizerpneumococcal conjugate vaccinePneumoniapneumonia vaccinePrevenar 13Prince Mathewvaccine
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok